Review article

https://doi.org/10.21860/medflum2022_280998

Causes of thrombocytopenia in COVID-19 patients

Dora Bežovan orcid.org/0000-0003-0877-3107 ; Sveučilište u Zagrebu, Medicinski fakultet, Zagreb, Hrvatska
Zdravko Mitrović orcid.org/0000-0002-9896-1234 ; Sveučilište u Zagrebu, Medicinski fakultet, Zagreb, Hrvatska, Klinička bolnica Dubrava, Klinika za unutarnje bolesti, Zavod za hematologiju, Zagreb, Hrvatska

Abstract

Thrombocytopenia is frequent in viral infections. Approximately 18% of COVID-19 patients have thrombocytopenia that is usually mild (ranging from 100 to 150 × 10^9/L). It is more common among critically ill whereby it is an independent risk factor for poor outcome and mortality. Both decreased production and increased consumption of platelets may contribute. Decreased platelet production may occur due to a damage to hematopoietic progenitors and capillary network of the lungs. The consumption of platelets is increased due to their hyperactivation and thrombotic microangiopathy. Immune thrombocytopenia (ITP) and drug-induced thrombocytopenia including heparin-induced thrombocytopenia (HIT) can also develop during COVID-19 treatment.

Keywords

COVID-19; SARS-CoV-2; thrombocytopenia

Hrčak ID:

280998

URI

https://hrcak.srce.hr/280998

Publication date:

1.9.2022.

Article data in other languages: croatian

Visits: 1.484 *